Print this page
Saturday, 19 December 2015 10:25

Anticoagulation news items. Weeks commencing 14th December 2015

Treatment for superficial infusion thrombophlebitis of the upper extremity

Cochrane Database of Systematic Reviews

Review of 13 studies (n=917) of a topical (11 studies), an oral and a parenteral treatment noted that evidence for treating acute infusion superficial thrombophlebitis is limited and of low quality and is insufficient to recommend the use of any of the treatments studied.


Polypharmacy and the Efficacy and Safety of Rivaroxaban versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation


In a population of patients in ROCKET AF, polypharmacy was not linked to higher risk of stroke or non-CNS embolism (NCE), but it was linked
to higher risks of combined endpoint of stroke, NCE, vascular death, or MI, and non-major clinically relevant or major bleeding.


Early Clinical and Radiological Course, Management, and Outcome of Intracerebral Hemorrhage Related to New Oral Anticoagulants

JAMA Neurology

In this observational study of 61 patients with non-traumatic NOAC-associated intracerebral haemorrhage admitted between 2012 and 2014 it
is reported that mortality was 28% and 65% of survivors had an unfavourable outcome at 3 months. Haematoma expansion occurred in 38%.


Safety of antithrombotic drugs in patients with atrial fibrillation and non-end-stage chronic kidney disease: Meta-analysis and systematic review

Thrombosis Reasearch

This review of 12 studies showed no significant difference in bleeding risk between warfarin and antiplatelets (RR 1.05; 95% CI = 0.74 to
1.36), but reduced bleeding risk with direct oral anticoagulants compared to warfarin (RR 0.81; 95% CI = 0.75 to 0.88).


Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy – sub-analysis of the AMPLIFY trial

Thrombosis and Haemostasis

Analysis of data from this RCT (n=5,395) comparing apixaban to enoxaparin followed by warfarin for treating venous thromboembolism showed
apixaban to be non-inferior at 7, 21, 90 days and 6 months and that the reduced bleeding risk with apixaban began early during treatment.



The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at: